Greg Parekh, PhD
Founder & Managing Partner
Greg Parekh is a Founder and Managing Partner of New Rhein, a Philadelphia based life sciences venture capital and private equity firm. Before launching New Rhein in 2011, Greg ran the Mergers & Acquisitions department for Novartis AG based in Basel Switzerland from 2004 to 2010 and led the integration planning for Alcon, its largest acquisition. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group in London from 1998 to 2004. Greg started his career in New York in 1994 as an associate and VP at Bear Stearns’ newly formed Life Sciences group.
Greg has served as a director for several of New Rhein’s portfolio companies including Novagali Pharma, SA (a Paris, France based ophthalmology company), Biocartis NV (a Belgian oncology diagnostics company, for which Greg also served as ad-interim Chief Executive Officer from 2011 to 2013), Chase Pharmaceuticals Inc. (an Irvine, CA based Alzheimer’s drug company), Softhale NV (a Belgian respiratory pharma company), Neuraptive Therapeutics, Inc. (a Philadelphia based nerve repair drug company), Butterfly Medical Ltd. (an Israeli Urology device company) and Alveus Inc. (a cardio-metabolic pharma company). In addition to his role at New Rhein, Greg is a FASCO member of the American Society of Clinical Oncology (ASCO) and served as director of CancerlinQ, ASCO’s wholly-owned big-data digital healthcare platform.
Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School and a dual-major B.A. in Economics and Political Science from the University of Rochester (magna cum laude). Greg lives in Brussels Belgium.